£13.5M
Calculus Capital led the financing round alongside several institutional investors to support platform development and pipeline progression.
LT
Laverock Therapeutics
Laverock Therapeutics develops a gene silencing platform for programmable advanced therapies.
London, UK—Founded 2021
£13.5MTotal raised
Laverock Therapeutics develops a gene silencing platform to create programmable advanced therapies for human applications. The firm commercialises the gene editing induced gene silencing technology.
Categories
Team
DV
David Venables
CEO